利拉鲁肽联合达格列净对2型糖尿病患者血糖、血脂水平及抗氧化指标的影响  

Effects of Liraglutide Combined with Dapagliflozin on Blood Glucose,Blood Lipids and Antioxidant Indexes in Patients with Type 2 Diabetes Mellitus

作　　者：刘瑶 张波 LIU Yao;ZHANG Bo(Pingxiang Mining Group Co.,LTD.General Hospital,Pingxiang Jiangxi 337000,China)

机构地区：[1]萍乡矿业集团有限责任公司总医院,江西萍乡337000

出　　处：《药品评价》2022年第18期1137-1140,共4页Drug Evaluation

摘　　要：目的:分析利拉鲁肽与达格列净联合治疗2型糖尿病患者的应用效果。方法:选取2020年6月至2022年2月萍乡矿业集团有限责任公司总医院收治的2型糖尿病患者86例,按随机数字表法分为两组,每组43例。对照组予以达格列净片治疗,研究组在对照组基础上加用利拉鲁肽治疗。对比两组患者血糖水平[餐后2 h血糖(2 h PG)、空腹血糖(FPG)、糖化血红蛋白(HbAlc)],血脂水平[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)],抗氧化指标[谷胱甘肽过氧化酶(GSH)、丙二醛(MDA)、过氧化脂质(LPO)]和不良反应发生情况。结果:连续治疗3个月后,研究组血糖水平均低于对照组,差异有统计学意义(P<0.05);研究组TC、TG、LDL-C水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);研究组抗氧化物指标均低于对照组,差异有统计学意义(P<0.05);两组不良反应率对比,差异无统计学意义(P>0.05)。结论:利拉鲁肽联合达格列净治疗T2DM,利于改善患者糖脂代谢指标水平,减轻氧化应激反应,临床应用效果较好,无明显不良反应,值得推广。Objective: Investigate the effects of liraglutide combined with dapagliflozin on blood glucose levels, blood lipids and antioxidant indexes in patients with type 2 diabetes mellitus. Methods: A total of 86 patients with type 2 diabetes mellitus admitted to Pingxiang Mining Group Co., LTD. General Hospital from June 2020 to February 2022 were selected and divided into two groups according to random number table method, with 43 patients in each group. The control group was treated with dapagliflozin tablets, and the study group additionally treated with liraglutide. Blood glucose levels [2 h postprandial plasma glucose(2 h PG),fasting blood glucose(FPG), glycated hemoglobin(HbAlc)], blood lipids levels [total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C)] and antioxidant indexes [glutathione peroxidase(GSH)], malondialdehyde(MDA), lipid peroxide(LPO)] and the incidence of adverse reactions were compared between 2 groups. Results: After three months of continuous treatment, the blood glucose level in the study group was lower than that in the control group(P<0.05). The levels of TC, TG and LDL-C in the study group were lower than those in the control group, while the HDL-C level was higher than that in the control group, with statistical differences(P<0.05). The antioxidant index of the study group was lower than that of the control group, and the difference was statistically significant(P<0.05). There was no statistical difference in the rate of adverse reactions between the two groups(P>0.05). Conclusion: Liraglutide combined with dapagliflozin in the treatment of T2DM is beneficial to improve glucose and lipid metabolism index level and reduce oxidative stress reaction.The clinical application effect is good, no obvious adverse reactions, worthy of promotion.

关 键 词：糖尿病 2型 利拉鲁肽 达格列净 血糖 血脂 抗氧化指标 

分 类 号：R587.1[医药卫生—内分泌]